Excessive sleepiness (ES) is a symptom of obstructive sleep apnea (OSA) and narcolepsy that has severe consequences. Wake-promoting drugs and stimulants are utilized as accessory treatment in OSA to reduce propensity to sleep but they do not improve sleep-disordered breathing. Solriamfetol is a first-line therapeutic agent to combat sleepiness in OSA and narcolepsy patients that is approved both by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For excessively sleepy adult patients with OSA despite primary treatment or narcolepsy patients without cataplexy, solriamfetol may be used as initial therapy or as replacement therapy in patients who fail treatment or experience unacceptable side effects with modafinil, armodafinil, pitolisant, or stimulants. It can also be used as add-on therapy in OSA or narcolepsy patients when ES is only partially controlled with modafinil, armodafinil, pitolisant, sodium oxybate, or stimulants. Solriamfetol is a phenylalanine derivative whose wake-promoting action may be mediated through its selective dopamine and norepinephrine reuptake inhibition. This paper reviews the profile of solriamfetol in treating ES associated with OSA or narcolepsy and discusses patient selection and clinical perspectives. Mechanism of action, pharmacology, pharmacokinetics, clinical efficacy, and tolerability of solriamfetol are described. https://www.selleckchem.com/products/glpg3970.html The Treatment of OSA and Narcolepsy Excessive Sleepiness (TONES) solriamfetol trials demonstrated the efficacy of solriamfetol in reducing propensity to sleep and maintaining wakefulness, with significant improvements in mean maintenance of wakefulness test (MWT) sleep latencies and significant reduction in Epworth Sleepiness Scale (ESS) scores compared to placebo. With solriamfetol, significantly higher percentages of patients showed improvement in patient's and clinician's global impression of change. To characterize the overall trends in early cases of COVID-19 and to identify the key points of the government effort to minimize the infection. A retrospective review and data were retrieved through online sources and the Saudi Ministry of Health daily announcements that were available online. The data included the number of infections per day, and the gender, nationality, location, source of infection, incidence, rate of recovery, and the rate mortality of COVID-19 patients in Saudi Arabia between March 1 and March 16, 2020. The incidence of COVID-19 increased in the first two weeks in Saudi Arabia, from zero cases on March 1 to more than 15 cases per day on March 16, with a total of 133 cases. The majority of patients were males (54.9%), of Saudi descent (54.9%), and had travel as their source of infection (57.1%). Most of the cases were in Makah (37.6%); however, there were increases in cases in all cities. Moreover, the Saudi government enacted several steps to minimize the spreading of infection. There was no statistical significance between source of infection with gender ( = 0.323). However, there was statistical significance between source of infection and nationality ( < 0.001). The incidence of COVID-19 cases is expected to continue to increase. However, the efforts of the Saudi government are crucial in minimizing the spread of this infection. The incidence of COVID-19 cases is expected to continue to increase. However, the efforts of the Saudi government are crucial in minimizing the spread of this infection. To develop a satisfaction scale of Chinese clinicians with Clinical Pathway (CP) implementation and evaluate its validity, reliability and item discrimination. Literature review, in-person interviews, and Delphi were used to design the scale. Data were collected in two phases using random sampling on the spot and an online survey. In the first phase, data from 239 clinicians were investigated in exploratory factor analysis. In the second phase, 513 valid questionnaires were collected and used for confirmatory factor analysis. The scale developed in this study has three dimensions (organization support, process identity, and effect perception) and a total of 21 items. Cronbach's alpha of each dimension was higher than 0.9. The 3-factor model had enough fitness (χ2/df = 5.602, NFI = 0.926, IFI = 0.938, CFI = 0.938, RFI = 0.914, TLI = 0.929, RMSEA = 0.095, RMR = 0.045). The standardized factor loadings of 21 variables were between 0.742 and 0.949. The average variance extracted (AVE) of each dimension was higher than 0.7, and the construct reliability (CR) of the dimensions was higher than 0.9. The Chi-square difference test results showed that the difference value between the unlimited and limited model of each two potential constructs was higher than 3.84 (P < 0.001). The clinicians' satisfaction scale developed in this study has good construct validity, convergent validity, discriminant validity, internal consistency, and item discrimination. This suggests its usefulness as a tool to assess the satisfaction of clinicians in the implementation of CP in China. The clinicians' satisfaction scale developed in this study has good construct validity, convergent validity, discriminant validity, internal consistency, and item discrimination. This suggests its usefulness as a tool to assess the satisfaction of clinicians in the implementation of CP in China. Mobile phones are widely used in hospital settings for different purposes. Mobile phones of healthcare workers (HCWs) could be colonized or harbor extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria and may act as source of infectious agents. The aim of this study was to determine the rate of extended-spectrum beta-lactamase-producing Gram-negative bacteria on mobile phones of healthcare workers, to assess their antimicrobial susceptibility patterns and associated factors. A laboratory-based cross-sectional study was conducted involving a total of 572 samples by rubbing swabs of the front screen, back, keypad, and metallic surfaces of mobile phones of healthcare workers using simple random sampling technique. All specimens were screened for ESBL using ESBL CHROME agar and confirmed using double-disk diffusion test (DDDT). Antibiotic susceptibility testing was done by the Kirby-Bauer disk diffusion technique on Mueller-Hinton agar. Data were analyzed using SPSS version 25, odds ratio and p-value was calculated to determine the association among variables.